The application of Montreal classification in different clinical and serological IBD Subtypes

Hepato-Gastroenterology

Volumn 57, Issue 101, 2010, Pages 787-793

  Mokrowiecka, Anna ^a   Kumor, Anna ^a   Jakubczyk, Ewa ^a   Pietruczuk, Mirosława ^a   Malecka Panas, Ewa ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

ASCA; Crohn's disease; pANCA; Ulcerative colitis

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN G ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ANUS DISEASE; ARTICLE; CLINICAL ASSESSMENT TOOL; CORTICOSTEROID THERAPY; CROHN DISEASE; DIAGNOSTIC KIT; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LARGE INTESTINE; MAJOR CLINICAL STUDY; MALE; MONTREAL CLASSIFICATION; PHENOTYPE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SEROLOGY; SMALL INTESTINE; ULCERATIVE COLITIS;

ADULT; AGED; ANTIBODIES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BODY MASS INDEX; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PHENOTYPE; SACCHAROMYCES CEREVISIAE; SEVERITY OF ILLNESS INDEX;

EID: 78149251516     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Sands BE: From symptom to diagnosis: clinical distinction among various forms of intestinal inflammation. Gastroenterology 2004; 126:1518-1532.
2. Plevy S: Do serological markers and cytokines determine the Indeterminate? J Clin Gastroenterol 2004; 38:S51-S56.
3. Abreu MT, Vasiliauskas EA, Kam LY, Dubinsky MC: Use of serologic tests in Crohn's disease. Clin Persp Gastroenterol 2001; 5/6:155-164.
4. Vasiliauskas EA, Plevy SE, Lanberg CJ: Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology 1996; 110:1810-1819.
5. Odze RD: Pathology of indeterminate colitis. J Clin Gastroenterol 2004; 38:S36-S40.
6. Warren BF: Classic pathology of ulcerative colitis and Crohn's disease. J Clin Gastroenterol 2004; 38:S33-S35.
7. Zholudev A, Zurakowski D, Young W, Leichtner A, Bousvaros A: Serologic testing with ANCA, ASCA, and Anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis diagnostic value and correlation with disease phenotype. Am J Gastroenterol 2004; 2235-2241.
8. Peeters M, Joossens S, Vermeire S, Vlietinck R, Bossuyt X, Rutgeerts P: Diagnostic value of anti-Sachcaromyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001; 96:730-734. (Pubitemid 32240723)
9. Koutroubakis IE, Petinaki E, Mouzas IA: Anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic autoantibodies in greek patients with IBD. Am J Gastroenterol 2001; 96:449-454.
10. Joossens S, Reinisch W, Vermeire S: The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 2002; 122:1242-1247.
11. Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55:749-753.
12. Chow DK, Leong RW, Lai LH, Wong GL, Leung WK, Chan FK, Sung JJ: Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm Bowel Dis 2008; 14:536-541.
13. Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; Suppl.24:2-6.
14. Best W: Rederived values of the eight coefficients of the Crohn's Disease Activity Index. Gastroenterology 1979; 77:843-846.
15. Rachmilewitz D: Coated mesalazine versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298:82-86.
16. Silverberg M, Satsangi J, Ahmad T: Toward an integrated clinical, molecular and serological classification of IBD: Report of the Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19:5A-15A.
17. Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH: Indeterminate colitis: a review of the concept-what's in a name? Inflamm Bowel Dis 2008; 14:850-857.
18. Lakatos PL, Szalay F, Tulassay Z: Clinical presentation of Crohn's disease. Association between familial disease, smoking, disease phenotype, extraintestinal manifestations and need for surgery. Hepato-Gastroenterol 2005; 52:817-822.
19. Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J: Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am J Gastroenterol 2007;102:577-588.
20. Polito JM, Childs B, Mellits ED: Crohn's disease: influence of age at diagnosis on site and clinical type of disesase. Gastroenterol 1996; 111:580-586. (Pubitemid 26293220)
21. Quinton JF, Sendid B, Reumaux D: Anti-Sachcaromyces cerevisiae mannan antibodies combined with ANCA in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998; 42:788-791.
22. Amre DK, Lu S-E, Costea F, Seidman EG: Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am J Gastroenterol 2006; 101:645-652.
23. Forcione DG, Rosen MJ, Kisiel JB: Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 2004; 53:1117-1122.
24. Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH: Clinical significance of antibodies against neutrophils in patients with IBD and primary sclerosing cholangitis. Gut 1992; 33:657-662.
25. Broekroelofs J, Mulder AH, Nelis GF: Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity. Dig Dis Sci 1994; 39:545-549.
26. Oudkerk Pool M, Ellerbroek PM, Ridwan BU: Serum ANCA in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between pANCA and clinical parameters, medical and surgical treatment. Gut 1993; 34:46-50.
27. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR: Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47:487-496.
28. Vecchi M, Gionchetti P, Bianchi MB, Belluzzi A, Meucci G, Camprieri M, de Franchis R: pANCA and development of pouchitis in UC patients after proctocolectomy and ileoanal pouch anastomosis. Lancet 1994; 344:886-887.
29. Stewenius J, Adnerhill I, Ekelund G: Operations in unselected patients with ulcerative colitis and indeterminate colitis. Eur J Surg 1996; 162:131-137. (Pubitemid 126441375)
30. Pearce CB, Lawrence IC: Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol 2007; 22:1671-1677.